The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 477-483

  Borst, Louise ^a   Wallerek, Sandra ^a   Dalhoff, Kim ^b   Rasmussen, Kirsten K ^a   Wesenberg, Finn ^c   Wehner, Peder S ^d   Schmiegelow, Kjeld ^a,e  

^a University of Copenhagen   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Childhood ALL; CYP3A5*3; Pharmacogenetics; Prognosis; Risk

Indexed keywords

CYTOCHROME P450 3A5; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; PRIMER DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLELE; ARTICLE; ASSOCIATION; CANCER RISK; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; DENMARK; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DENMARK; DISEASE-FREE SURVIVAL; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79955997150     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01608.x     Document Type: Article

References (34)

1. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 1995;159:113-21.
2. Swinney R, Hsu S, Tomlinson G. Phase I and Phase II enzyme polymorphisms and childhood cancer. J Investig Med 2006;54:303-20.
3. Bolufer P, Barragan E, Collado M, Cervera J, Lopez JA, Sanz MA. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 2006;30:1471-91.
4. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-65.
5. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, Taskinen M. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345-54.
6. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008;30:831-49.
7. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94.
8. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996;277:105-12.
9. Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-35.
10. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45:253-85.
11. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-47.
12. Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004;103:67-72.
13. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-55.
14. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-93.
15. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
16. Scelo G, Chokkalingam AP, Metayer C, Guha N, Barcellos LF, Wiemels JL, Wiencke JK, Buffler PA. Genetic polymorphisms in the cytochrome gene family and the risk of childhood acute lymphoblastic leukemia. Ejc Supplements 2008;6:207.
17. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151-7.
18. Pakakasama S, Mukda E, Sasanakul W, Kadegasem P, Udomsubpayakul U, Thithapandha A, Hongeng S. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 2005;79:202-5.
19. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005;105:4752-8.
20. Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003;122:240-4.
21. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004;22:3930-6.
22. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Makipernaa A, Nygaard R, Saarinen-Pihkala UM. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-75.
23. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
24. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 1995;86:248-9.
25. Rousset F. Genepop'007: a complete reimplementation of the Genepop software for Windows and Linux. Mol Ecol Resour 2008;8:103-6.
26. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162-72.
27. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;1:308-11.
28. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496-501.
29. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002;97:230-6.
30. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007;39:699-721.
31. Schmiegelow K, Vestergaard T, Nielsen SM, Hjalgrim H. Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis. Leukemia 2008;22:2137-41.
32. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, Van Wering ER, Veerman AJ. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 1998;12:1344-8.
33. Denton RR, Eisen LP, Elsasser MS, Harmon JM. Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines. Endocrinology 1993;133:248-56.
34. Pedersen KB, Vedeckis WV. Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry 2003;42:10978-90.